---
http_interactions:
- request:
    method: get
    uri: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?api_key=<NCBI_API_KEY>&db=pubmed&id=37194105
    body:
      encoding: US-ASCII
      string: ''
    headers:
      Accept-Encoding:
      - gzip;q=1.0,deflate;q=0.6,identity;q=0.3
      Accept:
      - "*/*"
      User-Agent:
      - Ruby
  response:
    status:
      code: 200
      message: OK
    headers:
      Date:
      - Wed, 17 May 2023 08:53:00 GMT
      Server:
      - Finatra
      Strict-Transport-Security:
      - max-age=31536000; includeSubDomains; preload
      Content-Security-Policy:
      - upgrade-insecure-requests
      Referrer-Policy:
      - origin-when-cross-origin
      Ncbi-Sid:
      - 1E0E752DD62B1C50_7135SID
      Ncbi-Phid:
      - 322C36E9C9D0D905000043C3F7F48A75.1.1.m_3
      Content-Type:
      - text/xml; charset=UTF-8
      Cache-Control:
      - private
      X-Ratelimit-Limit:
      - '10'
      X-Ratelimit-Remaining:
      - '9'
      Access-Control-Allow-Origin:
      - "*"
      Access-Control-Expose-Headers:
      - X-RateLimit-Limit,X-RateLimit-Remaining
      Set-Cookie:
      - ncbi_sid=1E0E752DD62B1C50_7135SID; domain=.nih.gov; path=/; expires=Fri, 17
        May 2024 08:53:01 GMT
      X-Ua-Compatible:
      - IE=Edge
      X-Xss-Protection:
      - 1; mode=block
      Transfer-Encoding:
      - chunked
    body:
      encoding: ASCII-8BIT
      string: |-
        <?xml version="1.0" ?>
        <!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
        <PubmedArticleSet>
        <PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37194105</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1475-2867</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>Cancer cell international</Title><ISOAbbreviation>Cancer Cell Int</ISOAbbreviation></Journal><ArticleTitle>Implications of CRNDE in prognosis, tumor immunity, and therapeutic sensitivity in low grade glioma patients.</ArticleTitle><Pagination><StartPage>93</StartPage><MedlinePgn>93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12935-023-02930-w</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Colorectal tumor differentially expressed (CRNDE) is specifically expressed in human brains and is the most highly expressed lncRNA in gliomas. Nevertheless, its implications in low grade glioma (LGG) are still indistinct. This study presented systematic analyses of CRNDE in LGG biology.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively retrieved TCGA, CGGC and GSE16011 LGG cohorts. Survival analysis was conducted for evaluating the prognostic significance of CRNDE in LGG. A CRNDE-based nomogram was established, and its predictive performance was verified. Signaling pathways underlying CRNDE were analyzed through ssGSEA and GSEA approaches. The abundance of immune cells and activity of cancer-immunity cycle were estimated with ssGSEA approach. Immune checkpoints, HLAs, chemokines, and immunotherapeutic response indicators (TIDE, and TMB) was quantified. U251 and SW1088 cells were transfected with specific shRNAs of CRNDE, and flow cytometry (apoptosis) and western blot (&#x3b2;-catenin and Wnt5a) assays were conducted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Up-regulated CRNDE was found in LGG, and was linked to unfavorable clinical outcomes. The CRNDE-based nomogram enabled to accurately predict patients' prognosis. High CRNDE expression was linked to more genomic variations, activity of tumorigenic pathways, tumor immunity (increase in infiltration of immune cells, expression of immune checkpoints, HLAs and chemokines, and cancer-immunity cycle), and therapeutic sensitivity. CRNDE knockdown mitigated malignant phenotypes of LGG cells.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study determined CRNDE as a novel predictor for patient prognosis, tumor immunity and therapeutic response in LGG. Assessment of CRNDE expression is a promising approach for predicting the therapeutic benefits of LGG patients.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, 361015, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jiang</LastName><ForeName>Yingchuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qiuping</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, 361015, Fujian, China. li.qiuping@zs-hospital.sh.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. li.qiuping@zs-hospital.sh.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Biao</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, 361015, Fujian, China. qi_biao@fudan.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cancer Cell Int</MedlineTA><NlmUniqueID>101139795</NlmUniqueID><ISSNLinking>1475-2867</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CRNDE</Keyword><Keyword MajorTopicYN="N">Low grade glioma</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Therapeutic sensitivity</Keyword><Keyword MajorTopicYN="N">Tumor immunity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37194105</ArticleId><ArticleId IdType="doi">10.1186/s12935-023-02930-w</ArticleId><ArticleId IdType="pii">10.1186/s12935-023-02930-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bornhorst M. New insights into the low-grade glioma tumor microenvironment for improved patient management. Neuro Oncol. 2022;24(1):27&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noab224</ArticleId><ArticleId IdType="pubmed">34515792</ArticleId></ArticleIdList></Reference><Reference><Citation>Bale TA, Rosenblum MK: The,. WHO classification of tumors of the central nervous system: an update on pediatric low-grade gliomas and glioneuronal tumors. Brain Pathol. 2021;2022: e13060.</Citation></Reference><Reference><Citation>Klein M, Drijver AJ, van den Bent MJ, Bromberg JC, Hoang-Xuan K, Taphoorn MJB, Reijneveld JC, Ben Hassel M, Vauleon E, Eekers DBP, et al. Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033&#x2013;26033. Neuro Oncol. 2021;23(5):803&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noaa252</ArticleId><ArticleId IdType="pubmed">33130890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Xie F, Wu Y, Wang L, Bai Y, Long J, Wang X. Differential genes and scoring criteria among immunogenomic clusters of lower-grade gliomas. Int Immunopharmacol. 2021;101(Pt B): 108376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108376</ArticleId><ArticleId IdType="pubmed">34815191</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang Y, Li J, Zhang Y, Yin H, Han B. CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling. Cancer Lett. 2015;367(2):122&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2015.03.027</ArticleId><ArticleId IdType="pubmed">25813405</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Liu M, Long W, Yuan J, Li H, Zhang C, Tang G, Jiang W, Yuan X, Wu M, et al. Knockdown lncRNA CRNDE enhances temozolomide chemosensitivity by regulating autophagy in glioblastoma. Cancer Cell Int. 2021;21(1):456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-021-02153-x</ArticleId><ArticleId IdType="pubmed">34454479</ArticleId><ArticleId IdType="pmc">8399846</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, Liu X, Wang P, Xue Y, Ma J, Qu C, Liu Y. CRNDE promotes malignant progression of glioma by attenuating miR-384/PIWIL4/STAT3 axis. Mol Ther. 2016;24(7):1199&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2016.71</ArticleId><ArticleId IdType="pubmed">27058823</ArticleId><ArticleId IdType="pmc">5088760</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorokin M, Raevskiy M, Zottel A, &#x160;amec N, Skoblar Vidmar M, Matja&#x161;i&#x10d; A, Zupan A, Mlakar J, Suntsova M, Kuzmin DV, et al. Large-scale transcriptomics-driven approach revealed overexpression of CRNDE as a poor survival prognosis biomarker in glioblastoma. Cancers. 2021;13(14):3419.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13143419</ArticleId><ArticleId IdType="pubmed">34298634</ArticleId><ArticleId IdType="pmc">8303503</ArticleId></ArticleIdList></Reference><Reference><Citation>Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8): e71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv1507</ArticleId><ArticleId IdType="pubmed">26704973</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.239244.118</ArticleId><ArticleId IdType="pubmed">30341162</ArticleId><ArticleId IdType="pmc">6211645</ArticleId></ArticleIdList></Reference><Reference><Citation>Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2011-12-4-r41</ArticleId><ArticleId IdType="pubmed">21527027</ArticleId><ArticleId IdType="pmc">3218867</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-14-7</ArticleId><ArticleId IdType="pubmed">23323831</ArticleId><ArticleId IdType="pmc">3618321</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberzon A, Birger C, Thorvaldsd&#xf3;ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2015.12.004</ArticleId><ArticleId IdType="pubmed">26771021</ArticleId><ArticleId IdType="pmc">4707969</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Niu X, Qiao X, Liu S, Ma H, Shi X, He X, Zhong M. Characterization of interplay between autophagy and ferroptosis and their synergistical roles on manipulating immunological tumor microenvironment in squamous cell carcinomas. Front Immunol. 2021;12: 739039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.739039</ArticleId><ArticleId IdType="pubmed">35185859</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId><ArticleId IdType="pmc">1239896</ArticleId></ArticleIdList></Reference><Reference><Citation>Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.12.019</ArticleId><ArticleId IdType="pubmed">28052254</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara K, Shahmoradgoli M, Mart&#xed;nez E, Vegesna R, Kim H, Torres-Garcia W, Trevi&#xf1;o V, Shen H, Laird PW, Levine DA, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3612</ArticleId><ArticleId IdType="pubmed">24113773</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Deng C, Pang B, Zhang X, Liu W, Liao G, Yuan H, Cheng P, Li F, Long Z, et al. TIP: a web server for resolving tumor immunophenotype profiling. Cancer Res. 2018;78(23):6575&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-18-0689</ArticleId><ArticleId IdType="pubmed">30154154</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0136-1</ArticleId><ArticleId IdType="pubmed">30127393</ArticleId><ArticleId IdType="pmc">6487502</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955-961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1111</ArticleId><ArticleId IdType="pubmed">23180760</ArticleId></ArticleIdList></Reference><Reference><Citation>Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9(9): e107468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0107468</ArticleId><ArticleId IdType="pubmed">25229481</ArticleId><ArticleId IdType="pmc">4167990</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell. 2018;33(4):676-689.e673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2018.03.007</ArticleId><ArticleId IdType="pubmed">29622463</ArticleId><ArticleId IdType="pmc">6028190</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al. The immune landscape of cancer. Immunity. 2019;51(2):411&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.08.004</ArticleId><ArticleId IdType="pubmed">31433971</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016;22(11):1342&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4191</ArticleId><ArticleId IdType="pubmed">27694933</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Wang Y, Yang T, Xing H, Wang Y, Gao L, Guo X, Xing B, Wang Y, Ma W. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients. Brief Bioinform. 2021. https://doi.org/10.1093/bib/bbab032 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbab032</ArticleId><ArticleId IdType="pubmed">34459479</ArticleId><ArticleId IdType="pmc">9630402</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Liu F, Li Y, Shen L. A 1p/19q codeletion-associated immune signature for predicting lower grade glioma prognosis. Cell Mol Neurobiol. 2022;42(3):709&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-020-00959-3</ArticleId><ArticleId IdType="pubmed">32894375</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, Chen L, Xu H, Long S, Jiang J, Wei W, Niu X, Li X. Application of nanomaterials in diagnosis and treatment of glioblastoma. Front Chem. 2022;10:1063152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2022.1063152</ArticleId><ArticleId IdType="pubmed">36569956</ArticleId><ArticleId IdType="pmc">9780288</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordell EC, Alghamri MS, Castro MG, Gutmann DH. T lymphocytes as dynamic regulators of glioma pathobiology. Neuro Oncol. 2022. https://doi.org/10.1093/neuonc/noac055 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noac055</ArticleId><ArticleId IdType="pubmed">35325210</ArticleId><ArticleId IdType="pmc">9165416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, et al. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. J Clin Invest. 2022;132(3):e151239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI151239</ArticleId><ArticleId IdType="pubmed">34882581</ArticleId><ArticleId IdType="pmc">8803342</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Wang H, Yu J, Yao X, Yang S, Li W, Xu L, Zhao L. LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM. Mol Cancer. 2021;20(1):6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-020-01299-y</ArticleId><ArticleId IdType="pubmed">33397371</ArticleId><ArticleId IdType="pmc">7780690</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin L, Zhou LQ, Liu C, Zeng F, Yuan YW, Zhou Q, Li SH, Wu Y, Wang JL, Wu DZ, et al. Transfer of LncRNA CRNDE in TAM-derived exosomes is linked with cisplatin resistance in gastric cancer. EMBO Rep. 2021;22(12): e52124.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.202052124</ArticleId><ArticleId IdType="pubmed">34647680</ArticleId><ArticleId IdType="pmc">8647143</ArticleId></ArticleIdList></Reference><Reference><Citation>Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu XY, Yu ZW, Jia YH, Bai XF, Li L, et al. The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/&#x3b2;-catenin signaling. Mol Cancer. 2017;16(1):9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-017-0583-1</ArticleId><ArticleId IdType="pubmed">28086904</ArticleId><ArticleId IdType="pmc">5237133</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao H, Song X, Kang T, Yan B, Feng L, Gao L, Ai L, Liu X, Yu J, Li H. Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. Onco Targets Ther. 2017;10:205&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S116178</ArticleId><ArticleId IdType="pubmed">28115855</ArticleId><ArticleId IdType="pmc">5221653</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S, Han B, Li Z, Sun D. Downregulation of long noncoding RNA CRNDE suppresses drug resistance of liver cancer cells by increasing microRNA-33a expression and decreasing HMGA2 expression. Cell Cycle. 2019;18(19):2524&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384101.2019.1652035</ArticleId><ArticleId IdType="pubmed">31416393</ArticleId><ArticleId IdType="pmc">6738913</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Sun L, Dai X, Li T, Yan X, Zhang Y, Xiao H, Shen X, Huang G, Xiang W, et al. LncRNA CRNDE promotes ATG4B-mediated autophagy and alleviates the sensitivity of sorafenib in hepatocellular carcinoma cells. Front Cell Dev Biol. 2021;9: 687524.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.687524</ArticleId><ArticleId IdType="pubmed">34409031</ArticleId><ArticleId IdType="pmc">8365422</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie SC, Zhang JQ, Jiang XL, Hua YY, Xie SW, Qin YA, Yang YJ. LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma. Cell Death Dis. 2020;11(8):676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-02853-8</ArticleId><ArticleId IdType="pubmed">32826865</ArticleId><ArticleId IdType="pmc">7442829</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang Y, Zhang S, Cao W, Wan D, Sun L. Knockdown of LncRNA CRNDE suppresses proliferation and P-glycoprotein-mediated multidrug resistance in acute myelocytic leukemia through the Wnt/&#x3b2;-catenin pathway. Biosci Rep. 2020;40(6):BSR20193450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20193450</ArticleId><ArticleId IdType="pubmed">32426817</ArticleId><ArticleId IdType="pmc">7273914</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi S, Noro R, Seike M, Zeng C, Matsumoto M, Yoshikawa A, Nakamichi S, Sugano T, Hirao M, Matsuda K, et al. Long non-coding RNA CRNDE is involved in resistance to EGFR tyrosine kinase inhibitor in EGFR-mutant lung cancer via eIF4A3/MUC1/EGFR signaling. Int J Mol Sci. 2021;22(8):4005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22084005</ArticleId><ArticleId IdType="pubmed">33924522</ArticleId><ArticleId IdType="pmc">8070547</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
  recorded_at: Wed, 17 May 2023 08:53:01 GMT
- request:
    method: get
    uri: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?api_key=<NCBI_API_KEY>&db=pubmed&id=37194105
    body:
      encoding: US-ASCII
      string: ''
    headers:
      Accept-Encoding:
      - gzip;q=1.0,deflate;q=0.6,identity;q=0.3
      Accept:
      - "*/*"
      User-Agent:
      - Ruby
  response:
    status:
      code: 200
      message: OK
    headers:
      Date:
      - Wed, 17 May 2023 08:53:01 GMT
      Server:
      - Finatra
      Strict-Transport-Security:
      - max-age=31536000; includeSubDomains; preload
      Content-Security-Policy:
      - upgrade-insecure-requests
      Referrer-Policy:
      - origin-when-cross-origin
      Ncbi-Sid:
      - 96A877A6B7D75664_D99DSID
      Ncbi-Phid:
      - 939B02350B33F335000041EF5FF5119F.1.1.m_3
      Content-Type:
      - text/xml; charset=UTF-8
      Cache-Control:
      - private
      X-Ratelimit-Limit:
      - '10'
      X-Ratelimit-Remaining:
      - '8'
      Access-Control-Allow-Origin:
      - "*"
      Access-Control-Expose-Headers:
      - X-RateLimit-Limit,X-RateLimit-Remaining
      Set-Cookie:
      - ncbi_sid=96A877A6B7D75664_D99DSID; domain=.nih.gov; path=/; expires=Fri, 17
        May 2024 08:53:02 GMT
      X-Ua-Compatible:
      - IE=Edge
      X-Xss-Protection:
      - 1; mode=block
      Transfer-Encoding:
      - chunked
    body:
      encoding: ASCII-8BIT
      string: |-
        <?xml version="1.0" ?>
        <!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
        <PubmedArticleSet>
        <PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37194105</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1475-2867</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>Cancer cell international</Title><ISOAbbreviation>Cancer Cell Int</ISOAbbreviation></Journal><ArticleTitle>Implications of CRNDE in prognosis, tumor immunity, and therapeutic sensitivity in low grade glioma patients.</ArticleTitle><Pagination><StartPage>93</StartPage><MedlinePgn>93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12935-023-02930-w</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Colorectal tumor differentially expressed (CRNDE) is specifically expressed in human brains and is the most highly expressed lncRNA in gliomas. Nevertheless, its implications in low grade glioma (LGG) are still indistinct. This study presented systematic analyses of CRNDE in LGG biology.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively retrieved TCGA, CGGC and GSE16011 LGG cohorts. Survival analysis was conducted for evaluating the prognostic significance of CRNDE in LGG. A CRNDE-based nomogram was established, and its predictive performance was verified. Signaling pathways underlying CRNDE were analyzed through ssGSEA and GSEA approaches. The abundance of immune cells and activity of cancer-immunity cycle were estimated with ssGSEA approach. Immune checkpoints, HLAs, chemokines, and immunotherapeutic response indicators (TIDE, and TMB) was quantified. U251 and SW1088 cells were transfected with specific shRNAs of CRNDE, and flow cytometry (apoptosis) and western blot (&#x3b2;-catenin and Wnt5a) assays were conducted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Up-regulated CRNDE was found in LGG, and was linked to unfavorable clinical outcomes. The CRNDE-based nomogram enabled to accurately predict patients' prognosis. High CRNDE expression was linked to more genomic variations, activity of tumorigenic pathways, tumor immunity (increase in infiltration of immune cells, expression of immune checkpoints, HLAs and chemokines, and cancer-immunity cycle), and therapeutic sensitivity. CRNDE knockdown mitigated malignant phenotypes of LGG cells.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study determined CRNDE as a novel predictor for patient prognosis, tumor immunity and therapeutic response in LGG. Assessment of CRNDE expression is a promising approach for predicting the therapeutic benefits of LGG patients.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, 361015, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jiang</LastName><ForeName>Yingchuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qiuping</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, 361015, Fujian, China. li.qiuping@zs-hospital.sh.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. li.qiuping@zs-hospital.sh.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Biao</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, 361015, Fujian, China. qi_biao@fudan.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cancer Cell Int</MedlineTA><NlmUniqueID>101139795</NlmUniqueID><ISSNLinking>1475-2867</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CRNDE</Keyword><Keyword MajorTopicYN="N">Low grade glioma</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Therapeutic sensitivity</Keyword><Keyword MajorTopicYN="N">Tumor immunity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37194105</ArticleId><ArticleId IdType="doi">10.1186/s12935-023-02930-w</ArticleId><ArticleId IdType="pii">10.1186/s12935-023-02930-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bornhorst M. New insights into the low-grade glioma tumor microenvironment for improved patient management. Neuro Oncol. 2022;24(1):27&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noab224</ArticleId><ArticleId IdType="pubmed">34515792</ArticleId></ArticleIdList></Reference><Reference><Citation>Bale TA, Rosenblum MK: The,. WHO classification of tumors of the central nervous system: an update on pediatric low-grade gliomas and glioneuronal tumors. Brain Pathol. 2021;2022: e13060.</Citation></Reference><Reference><Citation>Klein M, Drijver AJ, van den Bent MJ, Bromberg JC, Hoang-Xuan K, Taphoorn MJB, Reijneveld JC, Ben Hassel M, Vauleon E, Eekers DBP, et al. Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033&#x2013;26033. Neuro Oncol. 2021;23(5):803&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noaa252</ArticleId><ArticleId IdType="pubmed">33130890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Xie F, Wu Y, Wang L, Bai Y, Long J, Wang X. Differential genes and scoring criteria among immunogenomic clusters of lower-grade gliomas. Int Immunopharmacol. 2021;101(Pt B): 108376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108376</ArticleId><ArticleId IdType="pubmed">34815191</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang Y, Li J, Zhang Y, Yin H, Han B. CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling. Cancer Lett. 2015;367(2):122&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2015.03.027</ArticleId><ArticleId IdType="pubmed">25813405</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Liu M, Long W, Yuan J, Li H, Zhang C, Tang G, Jiang W, Yuan X, Wu M, et al. Knockdown lncRNA CRNDE enhances temozolomide chemosensitivity by regulating autophagy in glioblastoma. Cancer Cell Int. 2021;21(1):456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-021-02153-x</ArticleId><ArticleId IdType="pubmed">34454479</ArticleId><ArticleId IdType="pmc">8399846</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, Liu X, Wang P, Xue Y, Ma J, Qu C, Liu Y. CRNDE promotes malignant progression of glioma by attenuating miR-384/PIWIL4/STAT3 axis. Mol Ther. 2016;24(7):1199&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2016.71</ArticleId><ArticleId IdType="pubmed">27058823</ArticleId><ArticleId IdType="pmc">5088760</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorokin M, Raevskiy M, Zottel A, &#x160;amec N, Skoblar Vidmar M, Matja&#x161;i&#x10d; A, Zupan A, Mlakar J, Suntsova M, Kuzmin DV, et al. Large-scale transcriptomics-driven approach revealed overexpression of CRNDE as a poor survival prognosis biomarker in glioblastoma. Cancers. 2021;13(14):3419.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13143419</ArticleId><ArticleId IdType="pubmed">34298634</ArticleId><ArticleId IdType="pmc">8303503</ArticleId></ArticleIdList></Reference><Reference><Citation>Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8): e71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv1507</ArticleId><ArticleId IdType="pubmed">26704973</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.239244.118</ArticleId><ArticleId IdType="pubmed">30341162</ArticleId><ArticleId IdType="pmc">6211645</ArticleId></ArticleIdList></Reference><Reference><Citation>Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2011-12-4-r41</ArticleId><ArticleId IdType="pubmed">21527027</ArticleId><ArticleId IdType="pmc">3218867</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-14-7</ArticleId><ArticleId IdType="pubmed">23323831</ArticleId><ArticleId IdType="pmc">3618321</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberzon A, Birger C, Thorvaldsd&#xf3;ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2015.12.004</ArticleId><ArticleId IdType="pubmed">26771021</ArticleId><ArticleId IdType="pmc">4707969</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Niu X, Qiao X, Liu S, Ma H, Shi X, He X, Zhong M. Characterization of interplay between autophagy and ferroptosis and their synergistical roles on manipulating immunological tumor microenvironment in squamous cell carcinomas. Front Immunol. 2021;12: 739039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.739039</ArticleId><ArticleId IdType="pubmed">35185859</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId><ArticleId IdType="pmc">1239896</ArticleId></ArticleIdList></Reference><Reference><Citation>Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.12.019</ArticleId><ArticleId IdType="pubmed">28052254</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara K, Shahmoradgoli M, Mart&#xed;nez E, Vegesna R, Kim H, Torres-Garcia W, Trevi&#xf1;o V, Shen H, Laird PW, Levine DA, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3612</ArticleId><ArticleId IdType="pubmed">24113773</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Deng C, Pang B, Zhang X, Liu W, Liao G, Yuan H, Cheng P, Li F, Long Z, et al. TIP: a web server for resolving tumor immunophenotype profiling. Cancer Res. 2018;78(23):6575&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-18-0689</ArticleId><ArticleId IdType="pubmed">30154154</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0136-1</ArticleId><ArticleId IdType="pubmed">30127393</ArticleId><ArticleId IdType="pmc">6487502</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955-961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1111</ArticleId><ArticleId IdType="pubmed">23180760</ArticleId></ArticleIdList></Reference><Reference><Citation>Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9(9): e107468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0107468</ArticleId><ArticleId IdType="pubmed">25229481</ArticleId><ArticleId IdType="pmc">4167990</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell. 2018;33(4):676-689.e673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2018.03.007</ArticleId><ArticleId IdType="pubmed">29622463</ArticleId><ArticleId IdType="pmc">6028190</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al. The immune landscape of cancer. Immunity. 2019;51(2):411&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.08.004</ArticleId><ArticleId IdType="pubmed">31433971</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016;22(11):1342&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4191</ArticleId><ArticleId IdType="pubmed">27694933</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Wang Y, Yang T, Xing H, Wang Y, Gao L, Guo X, Xing B, Wang Y, Ma W. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients. Brief Bioinform. 2021. https://doi.org/10.1093/bib/bbab032 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbab032</ArticleId><ArticleId IdType="pubmed">34459479</ArticleId><ArticleId IdType="pmc">9630402</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Liu F, Li Y, Shen L. A 1p/19q codeletion-associated immune signature for predicting lower grade glioma prognosis. Cell Mol Neurobiol. 2022;42(3):709&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-020-00959-3</ArticleId><ArticleId IdType="pubmed">32894375</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, Chen L, Xu H, Long S, Jiang J, Wei W, Niu X, Li X. Application of nanomaterials in diagnosis and treatment of glioblastoma. Front Chem. 2022;10:1063152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2022.1063152</ArticleId><ArticleId IdType="pubmed">36569956</ArticleId><ArticleId IdType="pmc">9780288</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordell EC, Alghamri MS, Castro MG, Gutmann DH. T lymphocytes as dynamic regulators of glioma pathobiology. Neuro Oncol. 2022. https://doi.org/10.1093/neuonc/noac055 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noac055</ArticleId><ArticleId IdType="pubmed">35325210</ArticleId><ArticleId IdType="pmc">9165416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, et al. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. J Clin Invest. 2022;132(3):e151239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI151239</ArticleId><ArticleId IdType="pubmed">34882581</ArticleId><ArticleId IdType="pmc">8803342</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Wang H, Yu J, Yao X, Yang S, Li W, Xu L, Zhao L. LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM. Mol Cancer. 2021;20(1):6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-020-01299-y</ArticleId><ArticleId IdType="pubmed">33397371</ArticleId><ArticleId IdType="pmc">7780690</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin L, Zhou LQ, Liu C, Zeng F, Yuan YW, Zhou Q, Li SH, Wu Y, Wang JL, Wu DZ, et al. Transfer of LncRNA CRNDE in TAM-derived exosomes is linked with cisplatin resistance in gastric cancer. EMBO Rep. 2021;22(12): e52124.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.202052124</ArticleId><ArticleId IdType="pubmed">34647680</ArticleId><ArticleId IdType="pmc">8647143</ArticleId></ArticleIdList></Reference><Reference><Citation>Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu XY, Yu ZW, Jia YH, Bai XF, Li L, et al. The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/&#x3b2;-catenin signaling. Mol Cancer. 2017;16(1):9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-017-0583-1</ArticleId><ArticleId IdType="pubmed">28086904</ArticleId><ArticleId IdType="pmc">5237133</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao H, Song X, Kang T, Yan B, Feng L, Gao L, Ai L, Liu X, Yu J, Li H. Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. Onco Targets Ther. 2017;10:205&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S116178</ArticleId><ArticleId IdType="pubmed">28115855</ArticleId><ArticleId IdType="pmc">5221653</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S, Han B, Li Z, Sun D. Downregulation of long noncoding RNA CRNDE suppresses drug resistance of liver cancer cells by increasing microRNA-33a expression and decreasing HMGA2 expression. Cell Cycle. 2019;18(19):2524&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384101.2019.1652035</ArticleId><ArticleId IdType="pubmed">31416393</ArticleId><ArticleId IdType="pmc">6738913</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Sun L, Dai X, Li T, Yan X, Zhang Y, Xiao H, Shen X, Huang G, Xiang W, et al. LncRNA CRNDE promotes ATG4B-mediated autophagy and alleviates the sensitivity of sorafenib in hepatocellular carcinoma cells. Front Cell Dev Biol. 2021;9: 687524.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.687524</ArticleId><ArticleId IdType="pubmed">34409031</ArticleId><ArticleId IdType="pmc">8365422</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie SC, Zhang JQ, Jiang XL, Hua YY, Xie SW, Qin YA, Yang YJ. LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma. Cell Death Dis. 2020;11(8):676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-02853-8</ArticleId><ArticleId IdType="pubmed">32826865</ArticleId><ArticleId IdType="pmc">7442829</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang Y, Zhang S, Cao W, Wan D, Sun L. Knockdown of LncRNA CRNDE suppresses proliferation and P-glycoprotein-mediated multidrug resistance in acute myelocytic leukemia through the Wnt/&#x3b2;-catenin pathway. Biosci Rep. 2020;40(6):BSR20193450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20193450</ArticleId><ArticleId IdType="pubmed">32426817</ArticleId><ArticleId IdType="pmc">7273914</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi S, Noro R, Seike M, Zeng C, Matsumoto M, Yoshikawa A, Nakamichi S, Sugano T, Hirao M, Matsuda K, et al. Long non-coding RNA CRNDE is involved in resistance to EGFR tyrosine kinase inhibitor in EGFR-mutant lung cancer via eIF4A3/MUC1/EGFR signaling. Int J Mol Sci. 2021;22(8):4005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22084005</ArticleId><ArticleId IdType="pubmed">33924522</ArticleId><ArticleId IdType="pmc">8070547</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
  recorded_at: Wed, 17 May 2023 08:53:02 GMT
recorded_with: VCR 6.1.0
